Description

Icatibant acetate (HOE-140 acetate) is a potent and specific peptide antagonist of bradykinin B2 receptor with an IC50 and Ki of 1.07 nM and 0.798 nM respectively[1][2][3].–80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light)–COVID-19-immunoregulation–C61H93N19O15S—Adv Sci (Weinh). 2022 Oct 18;e2203088.|Biochem Biophys Res Commun. 2016 Apr 29;473(2):396-402. |Biomed Pharmacother. 2024 Mar 20:174:116489.|iScience. 2023 Jun 28.|J Renin Angiotensin Aldosterone Syst. 14 Jun 2022.|Nat Commun. 2023 May 2;14(1):2523.|Sci Rep. 2020 Aug 25;10(1):14160.|SSRN. 2023 Dec 27.-[1]Hock FJ, et al. Hoe 140 a new potent and long acting bradykinin-antagonist: in vitro studies. Br J Pharmacol. 1991 Mar;102(3):769-73.|[2]Y Arai, et al. Effect of Icatibant, a Bradykinin B2 Receptor Antagonist, on the Development of Experimental Ulcerative Colitis in Mice. Dig Dis Sci. 1999 Apr;44(4):845-51.|[3]Marie-Thérèse Bawolak, et al The Bradykinin B2 Receptor Antagonist Icatibant (Hoe 140) Blocks Aminopeptidase N at Micromolar Concentrations: Off-Target Alterations of Signaling Mediated by the Bradykinin B1 and Angiotensin Receptors. Eur J Pharmacol. 2006 Dec 3;551(1-3):108-11.–138614-30-9–1364.57–99.65–CC(O)=O.O=C([C@@H]1N(CC2=CC=CC=C2C1)C([C@H](CO)NC([C@@H](NC(CNC([C@H]3N(C[C@H](O)C3)C([C@H]4N(CCC4)C([C@H](CCCNC(N)=N)NC([C@H](N)CCCNC(N)=N)=O)=O)=O)=O)=O)CC5=CC=CS5)=O)=O)N6[C@]7([H])[C@](CCCC7)([H])C[C@H]6C(N[C@H](C(O)=O)CCCNC(N)=N)=O–Inflammation/Immunology–DMSO : 100 mg/mL (ultrasonic)–Bradykinin Receptor–Bradykinin B2 Receptor (B2R)–GPCR/G Protein–Peptides